Trial Profile
STAR: A randomised multiStage phase II/III trial of Standard first-line therapy (sunitinib or pazopanib) comparing Temporary cessation with Allowing continuation, in the firstline treatment of locally advanced and/or metastatic Renal cancer
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Feb 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms STAR
- 13 Feb 2023 Results assessing if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma published in the Lancet Oncology
- 01 Jan 2021 Status changed from active, no longer recruiting to completed.
- 05 Oct 2020 Planned End Date changed from 31 May 2017 to 31 Dec 2020.